R E G IS T R A T I O N D OS S I E R S A V A I L A B L E RE TAI L MA RKE T (WHOL ESAL ER S AND PH ARM AC IES) MOLECULE REFERENCE PRODUCT
Acyclovir Dexketoprofen
Solution for injection/Concentrate for solution for
Doxazosin
Fluoxetine Gabapentin Glimepiride
Glucosamine Sulphate
Ibuprofen-lysine
Memantine Mirtazapine Pantoprazole Quetiapine Venlafaxine
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.
R E G IS T R A T I O N D OS S I E R S A V A I L A B L E HOSPI TA L MA RKE T MOLECULE REFERENCE PRODUCT
Acyclovir
Lyophilised powder for solution for infusion
Amoxicillin + clavulanic acid
Cefepime
Cefonicid
Powder and solvent for solution for injection
Cefotaxime
Powder and solvent for solution for injection
Powder and solvent for solution for injection/infusion
Ceftazidime Powder and solvent for solution for injection
Ceftriaxone Powder and solvent for solution for injection Cis-atracurium
2 mg/mL (5 mL and 10 mL), 5 mg/mL (30 mL)
Cefuroxime (Sodium)
Powder and solvent for solution for injection
Powder for solution for injection/infusion
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.
R E G IS T R A T I O N D OS S I E R S A V A I L A B L E HOSPI TA L MA RKE T MOLECULE REFERENCE PRODUCT
Clindamycin
150 mg/ml (300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml)
Dexketoprofen
Solution for injection/Concentrate for solution for
Fluconazole
Flumazenil
Granisetron
Iron sucrose
Solution for injection/concentrate solution for infusion 20 mg/ml
Ketorolac Trometamol
Levofloxacin Meropenem
Midazolam
1 mg/ml (5 mg/5 ml), 5 mg/ml (15 mg/3 ml and 50 mg/10 ml)
Pamidronate
Lyophilised powder for solution for infusion
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries. April 2010
R E G IS T R A T I O N D OS S I E R S A V A I L A B L E HOSPI TA L MA RKE T MOLECULE REFERENCE PRODUCT Pantoprazole
Lyophilised powder for solution for injection/infusion
Paracetamol
Phenytoin
Piperacillin/Tazobactam Lyophilised powder and solvent for solution for injection
Lyophilised powder for solution for injection
Remifentanil
Lyophilised powder for solution for injection/infusion
Stilamin® (Serono, IT, NL, CH.)Somatostatin
Lyophilised powder and solvent for solution for infusion
Modustatine® (Clin Midy, FR.) Teicoplanina
Lyophilised powder and solvent for solution for injection
Vancomycin
Lyophilised powder for solution for injection
Zidovudine Capsules Zoledronic
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.
In re Montgomery The U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”) decision of In re Montgomery provides some illustration on the issue of anticipation by inherency in the therapeutic context. With its decision, the Federal Circuit sheds some light on the difficult doctrine of inherency, specifically on the potential importance of claim language and The U.S. pat
Press Release Chur/Altenrhein, 14/10/2009 "ALLEGRA": The first new RhB multiple unit train rolls out of the factory – A huge leap forwards for RhB customers October 14 2009 will go down as a milestone date in the history of Rhätische Bahn (RhB), as this was the day when the first of 15 new "ALLEGRA" series dual-voltage multiple unit trains left the Stadl
R E G IS T R A T I O N D OS S I E R S A V A I L A B L E 
R E G IS T R A T I O N D OS S I E R S A V A I L A B L E